Codexis Inc 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 or (Exact name of registrant as specified in its charter)_____________________________________________ Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and(2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”and “emerging growth company” in Rule12b-2 of the Exchange Act. Accelerated filer☐Smallerreportingcompany☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of August6, 2026, there were 109,505,765 shares of the registrant’s Common Stock, par value $0.0001 per share, outstanding. Codexis, Inc.Quarterly Report on Form 10-QFor the Quarter Ended June30, 2026 TABLE OF CONTENTS PART I. FINANCIAL INFORMATION ITEM1.Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Stockholders' EquityCondensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsITEM2.Management's Discussion and Analysis of Financial Condition and Results of OperationsITEM3.Quantitative and Qualitative Disclosures about Market RiskITEM4.Controls and Procedures PART II. OTHER INFORMATION ITEM1.Legal ProceedingsITEM1A.Risk FactorsITEM2.Unregistered Sales of Equity Securities and Use of ProceedsITEM3.Defaults Upon Senior SecuritiesITEM4.Mine Safety DisclosuresITEM5.Other InformationITEM6.ExhibitsSignatures “Codexis,” the Codexis logo, ECO Synthesis, ecoRNA, CodeEvolver and other trademarks or service marks of Codexis, Inc., appearing inthis Quarterly Report on Form 10-Q are the property of Codexis, Inc. This Quarterly Report on Form 10-Q contains additional tradenames, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks andtrade names referred to in this Quarterly Report on Form 10-Q may appear without theor ™ symbols.® Codexis, Inc.Condensed Consolidated Balance Sheets(Unaudited)(In Thousands, Except Per Share Amounts) Codexis, Inc.Condensed Consolidated Statements of Operations(Unaudited)(In Thousands, Except Per Share Amounts) Codexis, Inc.Condensed Consolidated Statements of Comprehensive Loss(Unaudited)(In Thousands) Codexis, Inc.Condensed Consolidated Statements of Stockholders' Equity(Unaudited)(In Thousands) Codexis, Inc.Condensed Consolidated Statements of Stockholders' Equity(Unaudited)(In Thousands) Codexis, Inc.Condensed Consolidated Statements of Cash Flows(Unaudited)(In Thousands) The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensedconsolidated balance sheets as of June30, 2026 and 2025 to the total of the same such amounts shown above in the unaudited condensedconsolidated statements of cash flows: See accompanying notes to the unaudited condensed consolidated financial statements. Codexis, Inc.Notes to Condensed Consolidated Financial Statements(Unaudited) Note 1. Description of Business In these notes to the unaudited condensed consolidated financial statements, the “Company,” “we,” “us,” and “our” refer to Codexis,Inc. and its subsidiaries on a consolidated basis. We discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins leveraging ourproprietary CodeEvolver directed evolution technology platform. We also offer an enzymatic alternative to solid-phase oligonucleotide synthesis using our ECO Synthesis manufacturing platform forfragment or full-length sequential synthesis of siRNA therapeutics. The Company's operations are managed and reported to the Chief Executive